DataSheet_1_Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients.pdf
Allogeneic stem cell transplantation survivors are at a relevant risk of developing chronic GvHD (cGvHD), which importantly affects quality of life and increases morbidity and mortality. Early identification of patients at risk of cGvHD-related morbidity could represent a relevant tool to tailor preventive strategies. The aim of this study was to evaluate the prognostic power of immune reconstitution (IR) at cGvHD onset through an IR-based score.
MethodsWe analyzed data from 411 adult patients consecutively transplanted between January 2011 and December 2016 at our Institution: 151 patients developed cGvHD (median follow-up 4 years). A first set of 111 consecutive patients with cGvHD entered the test cohort while an additional consecutive 40 patients represented the validation cohort. A Cox multivariate model for OS (overall survival) in patients with cGvHD of any severity allowed the identification of six variables independently predicting OS and TRM (transplant-related mortality). A formula for a prognostic risk index using the β coefficients derived from the model was designed. Each patient was assigned a score defining three groups of risk (low, intermediate, and high).
ResultsOur multivariate model defined the variables independently predicting OS at cGvHD onset: CD4+ >233 cells/mm3, NK <115 cells/mm3, IgA <0.43g/L, IgM <0.45g/L, Karnofsky PS <80%, platelets <100x103/mm3. Low-risk patients were defined as having a score ≤3.09, intermediate-risk patients >3.09 and ≤6.9, and high-risk patients >6.9. By ROC analysis, we identified a cut-off of 6.310 for both TRM and overall mortality.
In the training cohort, the 6-year OS and TRM from cGvHD occurrence were 85% (95% CI, 70-92) and 13% (95% CI, 5-25) for low-risk, 64% (95% CI, 44-89) and 30% (95% CI, 15-47) for intermediate-risk, 26% (95% CI, 10-47), and 42% (95% CI, 19-63) for high-risk patients (OS p<0.0001; TRM p = 0.015).
The validation cohort confirmed the model with a 6-year OS and TRM of 83% (95% CI, 48-96) and 8% (95% CI, 1-32) for low-risk, 78% (95% CI, 37-94) and 11% (95% CI, 1-41) for intermediate-risk, 37% (95% CI, 17-58), and 63% (95% CI, 36-81) for high-risk patients (OS p = 0.0075; TRM p = 0.0009).
ConclusionsIR score at diagnosis of cGvHD predicts GvHD severity and overall survival. IR score may contribute to the risk stratification of patients. If confirmed in a larger and multicenter-based study, IR score could be adopted to identify patients at high risk and modulate cGvHD treatments accordingly in the context of clinical trial.
History
References
- https://doi.org//10.1182/bloodadvances.2020003418
- https://doi.org//10.1053/j.seminhematol.2011.10.014
- https://doi.org//10.1056/NEJMra1703472
- https://doi.org//10.1038/leu.2015.212
- https://doi.org//10.1182/blood-2017-07-793786
- https://doi.org//10.1182/blood-2019-125986
- https://doi.org//10.1016/j.bbmt.2015.01.003
- https://doi.org//10.1038/s41409-018-0092-x
- https://doi.org//10.1016/j.bbmt.2008.11.024
- https://doi.org//10.1016/j.bbmt.2007.10.009
- https://doi.org//10.1182/blood-2008-09-177840
- https://doi.org//10.1182/blood-2004-03-1040
- https://doi.org//10.1182/blood-2005-03-1257
- https://doi.org//10.1016/j.leukres.2010.03.017
- https://doi.org//10.1097/TP.0b013e3181bc267e
- https://doi.org//10.1182/blood-2003-09-3286
- https://doi.org//10.1038/sj.leu.2404079
- https://doi.org//10.1182/blood-2010-12-323824
- https://doi.org//10.1016/j.bbmt.2014.10.022
- https://doi.org//10.1182/blood-2013-11-536581
- https://doi.org//10.1016/j.bbmt.2005.09.004
- https://doi.org//10.1016/j.bbmt.2014.12.001
- https://doi.org//10.1182/blood-2014-01-552984
- https://doi.org//10.1182/blood-2005-05-2004
- https://doi.org//10.1080/01621459.1958.10501452
- https://doi.org//10.1038/bmt.2013.107
- https://doi.org//10.1056/NEJM199907013410103
- https://doi.org//10.1182/blood-2014-08-551994
- https://doi.org//10.1016/j.bbmt.2017.10.042
- https://doi.org//10.1038/bmt.2013.97
- https://doi.org//10.1080/17474086.2020.1709436
- https://doi.org//10.1182/blood.2019003186
- https://doi.org//10.1182/blood-2015-10-672345
- https://doi.org//10.1182/blood-2014-12-567834
- https://doi.org//10.1080/14712598.2017.1369949
- https://doi.org//10.1038/sj.bmt.1705871
- https://doi.org//10.1182/bloodadvances.2017014464
- https://doi.org//10.1016/j.bbmt.2014.01.002
- https://doi.org//10.3324/haematol.2008.003103
- https://doi.org//10.1182/blood-2009-05-222190
- https://doi.org//10.1038/cmi.2013.56
- https://doi.org//10.1016/j.beha.2016.10.010
- https://doi.org//10.1182/blood-2017-05-780668
- https://doi.org//10.7150/jca.5049
- https://doi.org//10.1038/sj.leu.2404892
- https://doi.org//10.1016/j.bbmt.2007.12.497
- https://doi.org//10.1038/bmt.2010.306
- https://doi.org//10.1182/blood.v98.2.489
- https://doi.org//10.1016/j.bbmt.2018.11.007
- https://doi.org//10.3389/fimmu.2019.00782
- https://doi.org//10.1182/blood-2014-04-571125
- https://doi.org//10.1016/j.bbmt.2017.05.005